

Supplementary Online Content

Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. *JAMA Oncol*. Published online May 30, 2019. doi:10.1001/jamaoncol.2019.0892

eTable 1. Pathologic characteristics at surgery (N=34 resected patients)

eTable 2. Progression-free survival (PFS) and overall survival (OS)

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Pathologic characteristics at surgery (N=34 resected patients)

Characteristics	N (%)
Resection procedure	
Whipple	23 (68%)
Distal pancreatectomy	11 (32%)
Tumor size (cm)*	
Median	1.8
Range	0.0 - 6.2
Perineural invasion	
No	17 (50%)
Yes	17 (50%)
Lymphovascular invasion	
No	30 (88%)
Yes	4 (12%)
Margin status	
Negative	30 (88%)
Positive	4 (12%)
Nodal involvement	
No	25 (74%)
Yes	9 (26%)
Nodes assessed	
Median	17
Range	3 - 35
Nodes positive (among patients with nodal involvement)	
Median	1
Range	1 - 2

*Tumor dimensions unspecified in 5 patients due to scattered or microscopic foci

eTable 2. Progression-free survival (PFS) and overall survival (OS)

	All Eligible (N=49)	
	PFS	OS
Median (95% CI)	17.5 months (13.9 - 22.7)	31.4 months (18.1 - 38.5)
1-year (95% CI)	70.9% (55.0% - 82.1%)	84.3% (69.7% - 92.3%)
2-year (95% CI)	29.0% (15.1% - 44.6%)	57.3% (39.4% - 71.7%)
	Resected (N=34)	
	PFS	OS
Median (95% CI)	21.3 months (16.6 - 28.2)	33.0 months (31.4 - NR)
1-year (95% CI)	89.6% (70.8% - 96.5%)	97.1% (80.9% - 99.6%)
2-year (95% CI)	44.2% (23.5% - 63.1%)	82.9% (60.0% - 93.4%)

NR: not reached